Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 11/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637670 | 0.87 | CYP2D6 (0.74) | CYP2D6KCNH2 | |
| SCHEMBL3635825 | 0.84 | CYP2D6 (0.70) | CYP2D6KCNH2 | |
| SCHEMBL3021106 | 0.84 | CYP2D6 (1.00) | CYP2D6KCNH2ACHE | |
| SCHEMBL3031010 | 0.84 | CYP2D6 (1.00) | CYP2D6KCNH2ACHE | |
| SCHEMBL3031677 | 0.84 | CYP2D6 (1.00) | CYP2D6KCNH2ACHE | |
| SCHEMBL3032004 | 0.83 | CYP2D6 (0.78) | CYP2D6KCNH2ACHE | |
| Hydrochloric Acid SCHEMBL3036080 | 0.83 | CYP2D6 (0.98) | CYP2D6KCNH2ACHE | |
| SCHEMBL3020877 | 0.82 | CYP2D6 (0.77) | CYP2D6KCNH2 | |
| Hydrochloric Acid SCHEMBL3032495 | 0.81 | CYP2D6 (0.75) | CYP2D6KCNH2 | |
| SCHEMBL3025772 | 0.81 | CYP2D6 (0.75) | CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210631-A1 | SUBSTITUTED 2-[2-(PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS | CACNA1A, CACNA1B, SARAF | CYP2D6 3284/4885KCNH2 169/4885ADRB2 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.